cannabidiol (CHI-554) / Canopy Growth - LARVOL DELTA

Safety of Co-Administered CHI-554 and Alcohol (clinicaltrials.gov) - P1 | N=29 | Completed | Sponsor: Auburn University | Recruiting ➔ Completed

Trial completion

Safety of Co-Administered CHI-554 and Alcohol (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Canopy Growth Corporation | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date

CBD in Postmenopausal Women With Osteopenia (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Canopy Growth Corporation | Active, not recruiting ➔ Terminated; Low enrollment

Trial termination

Safety of Co-Administered CHI-554 and Alcohol (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Canopy Growth Corporation | Trial completion date: Jul 2022 ➔ Dec 2022 | Trial primary completion date: Jul 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date

CBD in Postmenopausal Women With Osteopenia (clinicaltrials.gov) - P1 | N=2 | Active, not recruiting | Sponsor: Canopy Growth Corporation | Recruiting ➔ Active, not recruiting | N=60 ➔ 2

Enrollment change • Enrollment closed